Sorafenib resistance in HCC is often mediated by the activation of alternative survival pathways like PI3K/AKT and compensatory mechanisms that inhibit cell death, including the glutathione (GSH) antioxidant system. The gene discussed is AKT1; the disease is hepatocellular carcinoma.